Immunomodulatory properties of transmembrane mucins: from chronic diseases to cancer
Physiological Reviews · 01.10.2025 · 105 (4) · 2233-2304
DOI: 10.1152/physrev.00034.2024 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Physiological Reviews, erschienen am 01.10.2025. Verfasst von Paula Montero und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Faculty of Medicine, University of Valencia, Valencia, Spain. Hauptthemen laut MEDLINE: Mucins, Neoplasms, Immunomodulation. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 511 Literaturangaben. Gefördert von: Ministerio de Ciencia e Innovación (MCIN), MEC | Instituto de Salud Carlos III (ISCIII), Centro de investigaci&ón en red de enfermedades respiratorias (CIBERES).
Abstract (Originalsprache)
Mucins are large glycoproteins that form the primary structural component of mucus and can be classified into secreted and transmembrane types. Of the 22 identified mucin genes, 12 encode transmembrane mucins, which play crucial roles in maintaining epithelial barrier integrity, modulating cell signaling, and innate immune responses to pathogens. Transmembrane mucins are expressed in epithelial cells, inflammatory cells, endothelial cells, and fibroblasts, influencing diverse cellular processes. They interact with extracellular ligands and transduce intracellular signals, functioning as membrane receptors with cell type-specific effects, triggering anti-inflammatory, proliferative, fibrotic, or carcinogenic processes. The extracellular domain of mucins can also be shed into the environment, where it exerts biological functions and serves as a biomarker for various chronic diseases. This review presents a comprehensive analysis of the discovery, structure, and molecular composition of different transmembrane mucins, along with their expression patterns and distribution across tissues. It explores their physiological roles and immunomodulatory functions and the diverse cellular processes they regulate. Furthermore, it discusses the contribution of transmembrane mucin gene variants, aberrant expression, and dysregulated activation in chronic diseases such as inflammation, fibrosis, and cancer. Finally, given the role of mucins in the progression of various pathologies, this review describes therapeutic strategies and biomarkers that have been translated into clinical practice with promising results, aiming to provide a comprehensive overview of the current understanding of transmembrane mucins.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, Faculty of Medicine, University of Valencia, Valencia, Spain.
- Faculty of Health Sciences, Universidad Europea de Valencia, Valencia, Spain.
- Biomedical Research Networking Centre on Respiratory Diseases (CIBERES), Health Institute Carlos III, Madrid, Spain.
- Pharmacy Unit, University General Hospital Consortium, Valencia, Spain.
ORCID-Profile: Paula Montero, Inés Roger, Javier Milara, Julio Cortijo
Förderung
- Ministerio de Ciencia e Innovación (MCIN)
- MEC | Instituto de Salud Carlos III (ISCIII)
- Centro de investigaci&ón en red de enfermedades respiratorias (CIBERES)
- Generalitat Valenciana (GVA)
Zitieren
APA
Montero, P., Roger, I., Milara, J., & Cortijo, J. (2025). Immunomodulatory properties of transmembrane mucins: from chronic diseases to cancer. Physiological Reviews, 105(4), 2233-2304. https://doi.org/10.1152/physrev.00034.2024
Vancouver
Montero P, Roger I, Milara J, Cortijo J. Immunomodulatory properties of transmembrane mucins: from chronic diseases to cancer. Physiological Reviews. 2025;105(4):2233-2304. doi:10.1152/physrev.00034.2024
BibTeX
@article{Montero2025,
author = {Montero, Paula and Roger, Inés and Milara, Javier and Cortijo, Julio},
title = {Immunomodulatory properties of transmembrane mucins: from chronic diseases to cancer},
journal = {Physiological Reviews},
year = {2025},
volume = {105},
number = {4},
pages = {2233--2304},
doi = {10.1152/physrev.00034.2024}
}
EUVIMED